Pemetrexed Disodium Injection, Powder, Lyophilized, For Solution
Product Images NDC 43598-387

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed Disodium (NDC 43598-387). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1gcarton (1gcarton)

Pemetrexed disodium for Injection, USP 1 g/vial lyophilized powder for solution is shown on a printed carton label. The label indicates intravenous use only, cautions it as a cytotoxic agent, and instructs to discard unused portions. The labeler is Dr. Reddys Laboratories Inc, and the product is made in India. Preparation and storage instructions are included on the label panels.*

FDA Label Image

1glabel (1glabel)

Label for Pemetrexed disodium injection, USP, 1 g/vial, a lyophilized powder for intravenous use. The label includes instructions for dilution and handling, warnings about cytotoxicity, and manufacturer information showing Dr. Reddys Laboratories Inc. as the labeler. The NDC number and barcode are also visible.*

FDA Label Image

Fig1 (Fig1)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months for two treatment arms labeled as A+P+C and A+C. The chart includes a legend and a table below indicating the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Fig2 (Fig2)

A survival probability curve illustrating overall survival over time in months for patients treated with pemetrexed plus cisplatin compared to cisplatin alone. The graph includes two lines showing decreasing survival probability with increasing survival time, accompanied by a table indicating patients at risk at various time points.*

FDA Label Image

Fig3 (Fig3)

A Kaplan-Meier survival curve chart comparing survival probability over time (in months) for two treatment groups: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The chart includes lines representing survival probabilities and a table below listing the number of patients at risk at various time points for each group.*

FDA Label Image

Fig4 (Fig4)

A survival curve chart comparing survival probability over time (in months) for two chemotherapy treatments: Pemetred + Cisplatin (AC) and Gemcitabine + Cisplatin (GC). The chart shows survival probability decreasing from 1.0 to near 0 over 30 months, with patient counts at risk displayed below the x-axis for each time point.*

FDA Label Image

Fig5 (Fig5)

A survival probability curve comparing Pemetrexed injection and placebo over a period of approximately 42 months. The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis, with two lines representing Pemetrexed and placebo. Below the graph, a table lists the number of patients at risk for each group at specific time points.*

FDA Label Image

Fig6 (Fig6)

A survival curve graph comparing Pemetrexed disodium injection and placebo. The y-axis represents survival probability, and the x-axis shows survival time in months. The graph includes patient risk counts at various time points for both Pemetrexed disodium and placebo groups.*

FDA Label Image

Fig7 (Fig7)

A survival probability chart comparing Pemetrexed disodium injection to placebo over a 42-month period. The x-axis represents survival time in months, and the y-axis shows survival probability. The lines depict survival trends for both Pemetrexed and placebo groups, with patient count at risk listed below.*

FDA Label Image

Fig8 (Fig8)

A survival probability Kaplan-Meier curve comparing Pemetrexed disodium injection and placebo over a period of up to 36 months. The graph features survival probability on the y-axis and survival time in months on the x-axis, with separate lines for Pemetrexed and placebo, including a table of patients at risk over time below the graph.*

FDA Label Image

Fig9 (Fig9)

A Kaplan-Meier survival curve graph comparing survival probability over time (up to 30 months) for patients treated with Pemetrexed plus Cisplatin versus Cisplatin alone. The x-axis represents survival time in months, and the y-axis represents survival probability. Below the graph is a table listing the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Car100 (Carton100)

Packaging label for Pemetrexed disodium injection, USP 100 mg per vial, lyophilized powder for intravenous use. The label states the product is cytotoxic and must be diluted prior to administration. It includes instructions for reconstitution and storage, cautionary notes, barcode, and the labeler Dr. Reddys Laboratories Inc. The vial is single-dose with no preservative.*

FDA Label Image

Car500 (Carton500)

Packaging label for Pemetrexed for Injection, USP 500 mg/vial, lyophilized powder for injection by intravenous use. The label specifies it is for a single-dose vial and includes warnings such as cytotoxic agent and discard unused portion. The labeler is Dr. Reddy's Laboratories Inc, with a distributor address in Princeton, NJ, and notes the product is made in India.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Pemetrexed disodium showing its molecular composition with sodium carboxylate groups and heterocyclic ring system.*

FDA Label Image

Vial100 (Vial100)

Label for Pemetrexed disodium injection, USP, 100 mg per vial, distributed by Dr. Reddys Laboratories Inc. The label indicates it is a single-dose vial for intravenous use, lyophilized powder requiring dilution, with a caution about cytotoxicity and instructions to discard unused portions. It features the NDC 43598-386-62 and storage instructions along with a barcode and manufacturer details.*

FDA Label Image

Vial500 (Vial500)

Label for Pemetrexed injection, USP 500 mg per vial, lyophilized powder for intravenous use by Dr. Reddys Laboratories Inc. The label includes dosing strength, storage instructions, a caution as a cytotoxic agent, directions to discard unused portions, and a barcode. The product is packaged as a single-dose vial.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.